title: Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
abstract: OBJECTIVE
  This phase II study evaluated the efficacy and safety of pegylated liposomal doxorubicin (PLD) 30 to 35 mg/m(2) plus oxaliplatin 70 mg/m(2) every 28 days in women with advanced ovarian cancer that recurred or progressed after a platinum-based regimen.
  
  
  METHODS
  43 women received a median of 6 courses of treatment.
  
  
  RESULTS
  Objective response was 54% in the evaluable population and was higher in women with platinum-sensitive (67%) compared with platinum-resistant disease (29%). At a median duration of follow-up of 15.5 months, median overall survival was 15.8 months and time to tumor progression 7.3 months. Most toxicity was no greater than grade 1 or 2. There was no grade 3 or 4 palmar-plantar erythrodysesthesia. After 264 cycles administered, neutropenia was the most common cause of severe toxicity and required one patient to withdraw from the study. No cardiotoxicity was reported.
  
  
  CONCLUSIONS
  PLD plus oxaliplatin is active and well tolerated in women with relapsed advanced ovarian cancer, regardless of platinum sensitivity.
authors.affiliation: Division of Medical Oncology, 35100 Padua PD, Italy. mariaorn@libero.it
authors.forename: M O
authors.initials: MO
authors.lastname: Nicoletto
authors.forename: C
authors.initials: C
authors.lastname: Falci
authors.forename: D
authors.initials: D
authors.lastname: Pianalto
authors.forename: G
authors.initials: G
authors.lastname: Artioli
authors.forename: P
authors.initials: P
authors.lastname: Azzoni
authors.forename: G
authors.initials: G
authors.lastname: De Masi
authors.forename: E
authors.initials: E
authors.lastname: Ferrazzi
authors.forename: A
authors.initials: A
authors.lastname: Perin
authors.forename: M
authors.initials: M
authors.lastname: Donach
authors.forename: W
authors.initials: W
authors.lastname: Zoli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000077150:Oxaliplatin; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D004317:Doxorubicin